TAKEOVER: viTAmin K2 and rEcOVery From ExeRcise
Study Details
Study Description
Brief Summary
The aim of the current study, therefore, is to investigate the effects of vitamin K2 supplementation on the physiological responses to an acute bout of resistance exercise.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Placebo Comparator: Placebo 380 mg capsule/day micro-crystalline cellulose |
Dietary Supplement: Micro-crystalline cellulose
Micro-crystalline cellulose
|
Active Comparator: Vitamin K2 380 mg capsule/day micro-crystalline cellulose including 240ug/day Vitamin K2 |
Dietary Supplement: Vitamin K2
Vitamin K2
|
Outcome Measures
Primary Outcome Measures
- Change in post exercise recovery of muscle strength [Change from baseline to 12 weeks]
Muscle strength (MVC) of the knee extensor muscles will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
Secondary Outcome Measures
- Change in pain free range of motion during knee extension exercise [Change from baseline to 12 weeks]
The range of motion which is pain free will be measured during knee extension using a goniometer before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
- Change in post exercise recovery of functional abilities [Change from baseline to 12 weeks]
Time to complete 5 chair rises will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
- Change in post exercise recovery of sEMG activity [Change from baseline to 12 weeks]
Quadriceps muscle sEMG will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
- Change in post exercise interleukin-6 [Change from baseline to 12 weeks]
Circulating interleukin-6 will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
- Change in post exercise peroxiredoxin 3 redox state [Change from baseline to 12 weeks]
Circulating peroxiredoxin 3 redox state will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
- Change in vitamin K levels [Change from baseline to 12 weeks]
Vitamin K will be measured in baseline and 12 week samples
- Change in Carboxylated Osteocalcin levels [Change from baseline to 12 weeks]
Carboxylated Osteocalcin will be measured in baseline and 12 week samples
- Change in uncarboxylated Osteocalcin levels [Change from baseline to 12 weeks]
uncarboxylated Osteocalcin will be measured in baseline and 12 week samples
- Change in carboxylated matrix gla-protein levels [Change from baseline to 12 weeks]
carboxylated matrix gla-protein will be measured in baseline and 12 week samples
- Change in dephosphorylated-uncarboxylated matrix gla-protein levels [Change from baseline to 12 weeks]
dephosphorylated-uncarboxylated matrix gla-protein will be measured in baseline and 12 week samples
- Change in post exercise F2 isoprostanes [Change from baseline to 12 weeks]
Circulating F2 isoprostanes will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
Other Outcome Measures
- Change in lean mass [Change from baseline to 12 weeks]
Change in lean mass
- Change in blood glucose [Change from baseline to 12 weeks]
Change in blood glucose
- Change in blood lipids [Change from baseline to 12 weeks]
Change in blood lipids
- Change in plasma insulin [Change from baseline to 12 weeks]
Change in plasma insulin
- Change in fat mass [Change from baseline to 12 weeks]
Change in fat mass
- Change in muscle thickness [Change from baseline to 12 weeks]
Change in muscle thickness
- Change in exercise substrate utilisation [Change from baseline to 12 weeks]
Energy expenditure, carbodhydrate and fat oxidation during treadmill walking
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participant is able and willing to sign the Informed Consent From
-
No plans to change lifestyle (activity and nutrition) during the study period
-
Older group (n=40): 65 years of age or older.
-
Younger group (n=40): Aged 18-40 years
Exclusion Criteria:
-
Not currently, or in the last year, participating in more than 1h per week of vigorous aerobic physical activity or any resistance exercise
-
BMI > 30 kg/m2
-
diabetes
-
severe cardiovascular disease
-
seizure disorders
-
liver disease
-
uncontrolled hypertension (>150/90mmHg at baseline measurement)
-
cancer or cancer that has been in remission <5 years
-
ambulatory impairments which would limit ability to perform assessments of muscle function
-
dementia
-
currently taking Vitamin K2 supplements
-
currently taking Vitamin K antagonists/anticoagulants (e.g. warfarin)
-
current smoking
-
history of drug abuse
-
taking medication known to affect muscle (e.g. steroids).
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Glasgow | Glasgow | United Kingdom | G12 8TA | |
2 | Stuart Robert Gray | Glasgow | United Kingdom |
Sponsors and Collaborators
- University of Glasgow
- Kappa Bioscience
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 200190189